July 2026 Update:
Since this article first ran, Ulixacaltamide has hit another major milestone. The FDA has accepted Praxis Precision Medicines’ New Drug Application for treating Essential Tremor in adults, meaning the application is officially complete and now under formal review. The agency has set a target decision date of January 29, 2027, under the Prescription Drug User Fee Act, and says it doesn’t currently plan to hold an advisory committee meeting as part of that review. Acceptance of an NDA doesn’t guarantee approval, but it’s still a meaningful step toward what could become one of the first medications developed specifically for Essential Tremor in decades. In the meantime, Praxis has already started gearing up for a possible launch, working on manufacturing, educating physicians, and planning distribution, all while it waits on the FDA’s final call.
For years, people living with Essential Tremor have had relatively few treatment options. Most medications prescribed today were not originally developed for Essential Tremor, and many patients either do not respond to them or eventually stop taking them because of side effects. That is why an announcement this week from Praxis Precision Medicines is drawing attention within the movement disorder community.
The company announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application for Ulixacaltamide, an investigational treatment for adults with Essential Tremor. The FDA has assigned the drug a target decision date of January 29, 2027. While this does not mean the medication has been approved, it does mean the FDA believes the application contains enough information to begin a formal review. The agency will now examine the drug’s safety, effectiveness, manufacturing information, and clinical trial data before making a final decision. For many Essential Tremor patients, the news represents something the field has been lacking for decades: a potential new medication specifically designed around what researchers believe is causing the tremor itself.
Essential Tremor affects an estimated seven million Americans and is considered the most common movement disorder. The condition causes involuntary shaking that most often affects the hands, but can also involve the head, voice, legs, and other parts of the body. Activities that most people take for granted, such as eating, drinking from a cup, writing a note, using a smartphone, or applying makeup, can become increasingly difficult as symptoms progress. Researchers now believe Essential Tremor is linked to abnormal signaling within a network involving the cerebellum, thalamus, and motor cortex. These areas of the brain help coordinate movement. When communication between them becomes disrupted, it can create the rhythmic, repetitive shaking associated with the condition.
Ulixacaltamide was designed to target part of that abnormal signaling pathway. The drug blocks T-type calcium channels, which researchers believe help contribute to the excessive electrical activity involved in tremor generation. Unlike many existing treatments that were adapted from other medical conditions, this therapy was specifically developed with Essential Tremor in mind. The application is supported by data from Praxis’ Phase 3 Essential3 clinical program. According to the company, patients receiving the treatment showed improvements not only in tremor severity but also in daily activities affected by tremor. Those activities included tasks such as eating, drinking, writing, and other routine functions that can have a significant impact on quality of life.
The road to this point was not entirely smooth. During development, an independent monitoring committee reviewed the study and suggested the trial could potentially be stopped because success appeared unlikely. Praxis chose to continue the program, and the final results ultimately met the study’s primary goals.
The FDA previously granted ulixacaltamide Breakthrough Therapy Designation, a designation reserved for investigational treatments that show the potential to offer meaningful improvements over currently available therapies. The agency has also indicated that it is not currently planning to hold an advisory committee meeting as part of the review process. If approved, ulixacaltamide could become one of the first major new pharmaceutical treatments for Essential Tremor in many years.
That possibility comes at an important time for the Essential Tremor community. Earlier this year, a review published by the International Parkinson and Movement Disorder Society concluded that many currently prescribed Essential Tremor medications lack the type of modern clinical evidence now expected in neurological research. While many patients continue to benefit from existing therapies, researchers emphasized the urgent need for better-designed studies and new treatment options.
Essential Tremor has often been viewed as a less urgent condition than disorders such as Parkinson’s disease, Huntington’s disease, or ALS because it is not typically fatal. Yet for millions of people, tremor can affect employment, independence, social interactions, and quality of life. Many patients avoid public situations, struggle with routine tasks, or experience anxiety and embarrassment because of their symptoms.
Whether ulixacaltamide ultimately receives FDA approval remains to be seen. The review process is still ongoing, and no outcome is guaranteed. What is clear, however, is that after decades of limited innovation, Essential Tremor research appears to be entering a period of renewed momentum. For patients who have waited years for new treatment options, that may be one of the most encouraging developments of all.
Discover more from
Subscribe to get the latest posts sent to your email.
